|
|
Prepublished online as a Blood First Edition Paper on June 5, 2003; DOI 10.1182/blood-2003-02-0444.
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2003, Vol. 102, No. 7, pp. 2345-2350
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
Ranjit K. Dasgupta,
Peter J. Adamson,
Faith E. Davies,
Sara Rollinson,
Philippa L. Roddam,
A. John Ashcroft,
Ann M. Dring,
James A. L. Fenton,
J. Anthony Child,
James M. Allan, and
Gareth J. Morgan
From the Academic Unit of Hematology and Oncology and the Epidemiology and Genetics Unit, University of Leeds, United Kingdom.
Glutathione S-transferase P1 (GSTP1) is a phase 2 drug metabolism enzyme involved in the metabolism and detoxification of a range of chemotherapeutic agents. A single nucleotide polymorphism (Ile105Val) results in a variant enzyme with lower thermal stability and altered catalytic activity. We hypothesized that patients with the less stable variant have a decreased ability to detoxify chemotherapeutic substrates, including melphalan, and have an altered outcome following treatment for multiple myeloma. We have assessed the impact of GSTP1 codon 105 polymorphisms in 222 patients entered into the Medical Research Council (MRC) myeloma VII trial (comparing standard-dose chemotherapy with high-dose therapy). In the standard-dose arm, patients with the variant allele (105Val) had an improved progression-free survival (PFS) (adjusted hazard ratios for PFS were 0.55 for heterozygotes and 0.52 for 105Val homozygotes, compared with 105Ile homozygotes; P for trend = .04); this was supported by a trend to improved overall survival, greater likelihood of entering plateau and shorter time to reach plateau in patients with the 105Val allele. No difference in outcome by genotype was found for patients treated with high-dose therapy. However, the progression-free survival advantage of the high-dose arm was seen only in patients homozygous for 105Ile (P = .008). (Blood. 2003;102:2345-2350)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. S. Huang, S. Duan, E. O. Kistner, W. K. Bleibel, S. M. Delaney, D. L. Fackenthal, S. Das, and M. E. Dolan
Genetic Variants Contributing to Daunorubicin-Induced Cytotoxicity
Cancer Res.,
May 1, 2008;
68(9):
3161 - 3168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa
Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors
J. Clin. Oncol.,
February 20, 2007;
25(6):
708 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schilthuizen, A. Broyl, B. van der Holt, Y. de Knegt, H. Lokhorst, and P. Sonneveld
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma
Haematologica,
February 1, 2007;
92(2):
277 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wrensch, A. McMillan, J. Wiencke, J. Wiemels, K. Kelsey, J. Patoka, H. Jones, V. Carlton, R. Miike, J. Sison, et al.
Nonsynonymous Coding Single-Nucleotide Polymorphisms Spanning the Genome in Relation to Glioblastoma Survival and Age at Diagnosis
Clin. Cancer Res.,
January 1, 2007;
13(1):
197 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen
Association of GSTP1 Polymorphism and Survival for Esophageal Cancer
Clin. Cancer Res.,
July 1, 2005;
11(13):
4749 - 4753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone
Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma
Clin. Cancer Res.,
March 15, 2005;
11(6):
2175 - 2179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Spitz, X. Wu, and G. Mills
Integrative Epidemiology: From Risk Assessment to Outcome Prediction
J. Clin. Oncol.,
January 10, 2005;
23(2):
267 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
